- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT00740519
Observational Study on Safety of Self-titration of Once Daily Levemir® (SOLVE™)
Evaluation on Safety of Self-titration in Insulin naïve People With Type 2 Diabetes Treated With Levemir® (Insulin Detemir) and Oral Antidiabetic Agents
This study is conducted in Europe. The main objective of the study is to assess the safety of self-titration in type 2 diabetic patients on antidiabetic tablets who are receiving insulin for the first time. The study will also look at the blood glucose control, frequency of dose adjustment, clinic visits, and time spent training patients to self-titrate.
The objective of diabetes management is to achieve blood glucose levels as close as possible to normal in order to avoid late stage diabetic complications. Self-titration (where patients adjust insulin dosage themselves) offers the potential for better blood glucose control than titration only at clinic visits. In recent years treatment of type 2 diabetes in the United Kingdom has moved from hospitals to GP surgeries or local clinics. Patients with type 2 diabetes, in general, have not been trained in self-titration to the same degree as patients with type 1 diabetes. Less experience in self-titration could impact the level of blood glucose control and outcome for these patients.
Data from this study will be pooled with data from NN304-3714 (NCT00825643) and will be reported in the final study report for NN304-3714.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Контакты и местонахождение
Места учебы
-
-
-
Crawley, Соединенное Королевство, RH11 9RT
- Novo Nordisk Investigational Site
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
- Ребенок
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Описание
Inclusion Criteria:
- After the participating physician/nurse's decision has been made to initiate once daily Levemir® therapy (within the license of the product), any patient with type 2 diabetes of 18 years or older who is currently treated with diet, exercise and one or more OADs can be offered to participate
Exclusion Criteria:
- Patients unable to give written informed consent
- Current treatment with insulin
- Patient deemed unable or unwilling to self-titrate
- Known or suspected allergy to study product or related products
- Pregnancy or breastfeeding or intention of becoming pregnant within the next 6 months
Учебный план
Как устроено исследование?
Детали дизайна
Когорты и вмешательства
Группа / когорта |
Вмешательство/лечение |
---|---|
А
|
Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Временное ограничение |
---|---|
Incidence of serious adverse drug reactions including major hypoglycaemic events
Временное ограничение: during treatment
|
during treatment
|
Вторичные показатели результатов
Мера результата |
Временное ограничение |
---|---|
Incidence of serious adverse events and all adverse events
Временное ограничение: during treatment
|
during treatment
|
Incidence of hypoglycaemic events
Временное ограничение: in the 4 weeks preceding the baseline, 12 and 20 week visits
|
in the 4 weeks preceding the baseline, 12 and 20 week visits
|
HbA1c
Временное ограничение: at the interim study visit at 12 weeks and the end of the study visit at 20 weeks
|
at the interim study visit at 12 weeks and the end of the study visit at 20 weeks
|
Variability and mean of the patient's self-monitored plasma glucose measurements
Временное ограничение: at approximately 12 and 20 weeks
|
at approximately 12 and 20 weeks
|
Proportion of patients who achieved equal or greater than 1% HbA1c reduction after initiation of insulin detemir without experiencing hypoglycaemic episodes
Временное ограничение: at approximately 12 and 20 weeks
|
at approximately 12 and 20 weeks
|
Proportion of patients achieving FBG below 6.0 mmol/l +/- hypo
Временное ограничение: defined by the average of the last three FBGs
|
defined by the average of the last three FBGs
|
Body weight
Временное ограничение: at approximately 12 and 20 weeks
|
at approximately 12 and 20 weeks
|
Frequency of insulin adjustment
Временное ограничение: at approximately 12 and 20 weeks
|
at approximately 12 and 20 weeks
|
Total number of visits/contacts to the clinic, related to titration
Временное ограничение: at approximately 12 and 20 weeks
|
at approximately 12 and 20 weeks
|
HCP time used on titration training
Временное ограничение: at baseline and approximately 12 and 20 weeks
|
at baseline and approximately 12 and 20 weeks
|
Соавторы и исследователи
Спонсор
Публикации и полезные ссылки
Общие публикации
- Khunti K, Damci T, Meneghini L, Pan CY, Yale JF; SOLVE Study Group. Study of Once Daily Levemir (SOLVE): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes Obes Metab. 2012 Jul;14(7):654-61. doi: 10.1111/j.1463-1326.2012.01602.x. Epub 2012 Apr 22.
- Ross S, Dzida G, Ji Q, Kaiser M, Ligthelm R, Meneghini L, Nazeri A, Orozco-Beltran D, Pan C, Svendsen AL; SOLVE Study Group. Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice. J Diabetes. 2014 May;6(3):243-50. doi: 10.1111/1753-0407.12091. Epub 2013 Oct 29.
- Vora J, Caputo S, Damci T, Orozco-Beltran D, Pan C, Svendsen AL, Solje KS, Khunti K; SOLVE study group. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes. J Clin Pharm Ther. 2014 Apr;39(2):136-43. doi: 10.1111/jcpt.12116. Epub 2013 Dec 13.
- Khunti K, Vora J, Davies M. Results from the UK cohort of SOLVE: providing insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Prim Care Diabetes. 2014 Apr;8(1):57-63. doi: 10.1016/j.pcd.2013.11.010. Epub 2013 Dec 27.
- Khunti K, Damci T, Husemoen LL, Babu V, Liebl A. Exploring the characteristics of suboptimally controlled patients after 24weeks of basal insulin treatment: An individualized approach to intensification. Diabetes Res Clin Pract. 2017 Jan;123:209-217. doi: 10.1016/j.diabres.2016.11.028. Epub 2016 Dec 9.
- Orozco-Beltran D, Pan C, Svendsen AL, Faerch L, Caputo S; SOLVE Study Group. Basal insulin initiation in primary vs. specialist care: similar glycaemic control in two different patient populations. Int J Clin Pract. 2016 Mar;70(3):236-43. doi: 10.1111/ijcp.12776. Epub 2016 Feb 24.
- Damci T, Emral R, Svendsen AL, Balkir T, Vora J; SOLVE study group. Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study. BMC Endocr Disord. 2014 Jul 21;14:61. doi: 10.1186/1472-6823-14-61.
- Yale JF, Damci T, Kaiser M, Karnieli E, Khunti K, Liebl A, Baeres FM, Svendsen AL, Ross SA; SOLVE Study Group. Initiation of once daily insulin detemir is not associated with weight gain in patients with type 2 diabetes mellitus: results from an observational study. Diabetol Metab Syndr. 2013 Oct 2;5(1):56. doi: 10.1186/1758-5996-5-56.
- Liebl A, Andersen H, Svendsen AL, Vora J, Yale JF; SOLVE Study Group. Resource utilisation and quality of life following initiation of insulin detemir in patients with type 2 diabetes mellitus. Int J Clin Pract. 2013 Aug;67(8):740-9. doi: 10.1111/ijcp.12133.
- Karnieli E, Baeres FM, Dzida G, Ji Q, Ligthelm R, Ross S, Svendsen AL, Yale JF; SOLVE Study Group. Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years or older: a sub-analysis of data from the Study of Once daily LeVEmir (SOLVE). Drugs Aging. 2013 Mar;30(3):167-75. doi: 10.1007/s40266-013-0054-3.
- Liebl A, Wilhelm B, Kaiser M. [Once daily insulin detemir in patients with type 2 diabetes: results of German centers in a 6-month international observational study (SOLVE)]. MMW Fortschr Med. 2012 Dec 17;154 Suppl 4:102-9. German.
Полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- NN304-3573
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования insulin detemir
-
Michael TsoukasAdociaРекрутинг
-
Rush University Medical CenterNovo Nordisk A/SЗавершенныйДиабетический кетоацидозСоединенные Штаты
-
Eli Lilly and CompanyЗавершенныйСахарный диабет, тип 2Канада, Индия, Румыния, Испания, Мексика, Турция, Португалия, Египет
-
Mannkind CorporationЗавершенныйСахарный диабет 1 типаСоединенные Штаты, Бразилия, Российская Федерация, Украина
-
Julphar Gulf Pharmaceutical IndustriesParexel; Profil Institut für Stoffwechselforschung GmbHЗавершенный
-
Julphar Gulf Pharmaceutical IndustriesProfil Institut für Stoffwechselforschung GmbHЗавершенный